Search results
Added:
2 months ago
Jozine ter Maaten
Research Area(s) / Expertise:
Job title: Cardiologist
Author
Added:
1 year ago
ESC-HFA 23 –Dr Ross Campbell (University of Glasgow, UK)joins us onsite to discuss the findings of the DAPA-RESIST Trial, which aimed to assess the affect of dapagliflozin as compared to metolazone in heart failure patients with diuretic resistance (NCT04860011).
In this phase 3 trial, investigators studied whether SGLT2i led to greater diuresis in this patient group, as to the standard practice…
View more
Added:
1 year ago
ESC 2023 — Dr Jozine Ter Maaten (University Medical Centre Groningen, NL) joins us to outline the findings from the PUSH-AHF Study (NCT04606927).
PUSH-AHF (University Medical Center Groningen) aimed to assess the effect of natriuresis-guided therapy in patients with acute heart failure to improve diagnostic response, decongestion and clinical outcomes. 310 patients with a primary diagnosis of…
View more
Added:
1 year ago
ESC-HFA 2023 – Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) joined by Dr James Januzzi (Massachusetts General Hospital, US) to discuss late-breaking science highlights of this year's ESC Heart Failure.
Trials covered in details include:
1:13: First-in-Human Study of NI006 in Patients With Amyloid Transthyretin Cardiomyopathy
1:42: TRACER-HF:Trientine-HCL for treatment of…
View more
Added:
2 months ago
THT Conference 2025 - Positive safety and efficacy outcomes were found of the Reprieve decongestion management system (DMS; Reprieve Cardiovascular, Inc) for the treatment of acute decompensated heart failure (ADHF). Urinary sodium excretion was seen to be significantly higher in the Reprieve DMS arm than in the control arm, and there were fewer UTI infections in ADHF patients receiving the…
View more
Added:
1 year ago
ESC-HFA 2023 — Dr Jasper Brugts (Thoraxcenter, NL) joins us to outline the findings and summarise the take-home messages from the MONITOR-HF trial (NTR7672).
MONITOR-HF was an open-label, randomised trial, done in 25 centres in the Netherlands. Eligible patients had chronic heart failure of New York Heart Association class III and a previous heart failure hospitalisation, irrespective of…
View more
Added:
1 year ago
ESC-HFA 23 — Dr Stephen Greene (Duke University School of Medicine, US) outlines the findings from the QoL study of the TRANSFORM-HF Trial (NCT03296813).
The TRANSFORM-HF trial is a randomized trial which compared torsemide to furosemide as a treatment for patients with heart failure. Around 2859 patients with heart failure were enrolled in the trial, whose clinical outcomes were measured across…
View more
‘Residual Congestion’ in HF
Added:
3 weeks ago
Article
Added:
11 months ago
HFA 2024 — Join experts, Dr Harriette Van Spall (McMaster University, CA) and Dr Mark Petrie (University of Glasgow, UK) for an insightful wrap up of the novel data presented at 2024's Heart Failure Congress.00:24 - STEP HFpEF Programme: Semaglutide 2.4 mg and NTproBNP in obesity-related HFpEF & Semaglutide therapy and diuretic use in obesity-related HFpEF02:20 - EMPACT-MI: The effect of…
View more
